Search

Displaying results 2401 - 2410 of 10000 in total
  1. Drug

    Benfluorex

    go.drugbank.com/drugs/DB09022
    ApprovedWithdrawn

    The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009. … This recommendation was based on the risks (especially fenfluramine-like cardiovascular side-effects) outweighing the benefits.

    Categories: Drugs Used in Diabetes
  2. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … [A214280, A214295] On January 16, 2024, inebilizumab also received Health Canada approval for the same indication.

  3. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein. … [A260256] DMD tends to be more prevalent in males.

  4. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    [A241065] Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation. … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.

  5. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    [A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric … a 68% reduction in the risk of death were observed.

  6. Drug

    Rifalazil

    go.drugbank.com/drugs/DB04934
    Investigational

    Rifalazil is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections.

  7. Drug

    Edoxudine

    go.drugbank.com/drugs/DB13421
    ApprovedWithdrawn

    It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … The obtained product is an antiviral ointment.[L2407] The activity of edoxudine against herpes simplex virus was first recognized in 1967.

  8. Drug

    Tipiracil

    go.drugbank.com/drugs/DB09343
    ApprovedInvestigational

    It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. … [A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF

  9. Drug

    Ibalizumab

    go.drugbank.com/drugs/DB12698
    ApprovedInvestigational

    It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies [L1558, L1554]. … This drug was approved in March 2018 for the management of treatment-resistant HIV [L1554].

  10. Drug

    Ziconotide

    go.drugbank.com/drugs/DB06283
    ApprovedInvestigational

    [A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling. … [A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be

    Categories: Calcium Channels, N-Type, N-Calcium Channel Receptor Antagonists